First- and Second-Generation Antipsychotics for Children and Young Adults
Introduction to Antipsychotics in Pediatric Use (2 of 4)
First-generation antipsychotics (FGAs) are associated with side effects that are difficult to manage and in some cases are irreversible. Neurological side effects include extrapyramidal system movement disorders. Some serious adverse effects that occur with use of FGAs are tardive dyskinesia with repetitive, involuntary muscle movements; akathisia, characterized by restlessness; and the inability to initiate movement, a Parkinson’s disease-like symptom. Development of the second-generation antipsychotics was driven by the desire to limit neuromotor adverse effects.
- Seida J, Schouten J, Mousavi S, et al. First- and Second-Generation Antipsychotics for Children and Young Adults. Comparative Effectiveness Review No. 39 (Prepared by the University of Alberta Evidence-based Practice Center under Contract No. 290-2007-10021). Rockville, MD: Agency for Healthcare Research and Quality; February 2012. AHRQ Publication No. 11(12)-EHC077-EF. Available at www.effectivehealthcare.ahrq.gov/pedantipsych.cfm.
- Jensen PS, Buitelaar J, Pandina GJ, et al. Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials. Eur Child Adolesc Psychiatry 2007;16(2):104–20. PMID: 17075688.
- Zito JM, Derivan AT, Kratochvil CJ, et al. Off-label psychopharmacologic prescribing for children: history supports close clinical monitoring. Child Adolesc Psychiatry Ment Health 2008;2(1):24–34. PMID: 18793403.
Your slide tray is being processed.